Latest News and Press Releases

Oslo, Norway, 22 April 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, has successfully...

Oslo, Norway, 4 April, 2025 - Reference is made to the stock exchange notice published by Zelluna ASA (the "Company") on 27 March 2025 regarding key information on the reverse share split at a ratio...

Oslo, April 04, 2025, the Board of Directors hereby calls for the Annual General Meeting of Zelluna ASA at 14:00 CET on April 29, 2025.  The General Meeting will be held electronically. For...

Oslo, Norway, 02 April, 2025 - Zelluna ASA, a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces that the Board of...

Oslo, Norway, 1 April 2025 Issuer name: Zelluna ASAEx. date: 1 April 2025Type of corporate action: Reverse share split Other information:Reverse split ratio – ten (10) old shares give one (1) new...

Oslo, Norway, 31 March, 2025 Reference is made to the stock exchange notice published by the Zelluna ASA (the "Company") on 27 March 2025 with key information concerning a reverse share split in the...

Oslo, Norway, 27 March, 2025 Reference is made to the stock exchange notice published on 9 January 2025 regarding an extraordinary general meeting held in Zelluna ASA (the "Company"), where it was...

Oslo, Norway, 27 March, 2025 Reference is made to the stock exchange notice published on 26 March 2025 regarding the resolution of the board of directors of Zelluna ASA (the "Company") to carry out a...

Oslo, Norway, 26 March, 2025 Reference is made to the stock exchange notice published by Zelluna ASA (the "Company") published on 26 March 2025 regarding the resolution by the Company's board of...

Oslo, Norway, 26 March, 2025 Reference is made to the stock exchange notice published on 9 January 2025 regarding an extraordinary general meeting held in Zelluna ASA (the "Company"), where it was...